Skip to main content

Table 5 Odds ratios for breast cancer according to duration for 'exclusive use' of individual SSRIs

From: A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: The impact of duration of use, cumulative dose and latency

No. of SSRI
prescriptions
Exclusive use a
  Cases Controls Unadjusted OR b
(95% CI)
Adjusted OR c
(95% CI)
  n (%) n (%)   
No use d (reference) 1,442 (84.8) 14,415 (84.7) 1.00 1.00
Paroxetine       
1 to 23 57 (3.8) 482 (3.2) 1.18 (0.89, 1.56) 1.17 (0.88, 1.55)
≥24 11 (0.73) 89 (0.6) 1.24 (0.66, 2.32) 1.20 (0.64, 2.25)
Sertraline       
1 to 23 22 (1.5) 240 (1.6) 0.92 (0.59, 1.42) 0.92 (0.59, 1.42)
≥24 8 (0.5) 44 (0.3) 1.82 (0.85, 3.87) 1.84 (0.86, 3.93)
Fluoxetine       
1 to 23 38 (2.6) 483 (3.2) 0.79 (0.56, 1.10) 0.79 (0.56, 1.10)
≥24 1 (0.7) 134 (0.9) 0.82 (0.44, 1.52) 0.81 (0.44, 1.51)
Fluvoxamine       
1 to 23 18 (1.2) 174 (1.2) 1.03 (0.64, 1.69) 1.02 (0.63, 1.67)
≥24 4 (0.3) 30 (0.2) 1.33 (0.47, 3.79) 1.33 (0.47, 3.77)
Citalopram e       
1 to 23 9 (0.6) 133 (0.9) Not estimatable Not estimatable
≥24 0 (0.0) 9 (0.1)   
  1. OR = odds ratio; CI = confidence interval
  2. a 'Exclusive use' refers to use of only one type of SSRI during the exposure time window two or more years prior to index date.
  3. b Matched on age in five-year age groups but unadjusted for the influence of other risk factors.
  4. c Adjusted for age at index (years), marital status, income support status, residence status, and use of oral contraceptives and/or use of hormone therapy.
  5. d 'No use' (reference category) refers to women with no SSRI prescriptions dispensed two or more years prior to index date.
  6. e Small sample sizes did not allow a complete evaluation of risk for 'exclusive use' of citalopram.